Clinical Trial: The Dose-Response Relationship of Rocuronium in Patients Taking Pyridostigmine

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Observational

Official Title: The Dose-response Relationship of Rocuronium in Patients Taking Pyridostigmine Preoperatively Compared With Age and Sex Matched Controls

Brief Summary: Pyridostigmine is a medication that is used in certain heart rate and blood pressure conditions. This medication, as a side effect, is known to also cause changes in the junction between a nerve and muscle. The changes caused at the nerve muscle junction by pyridostigmine could alter the effect of muscle relaxants (a medication used during surgery and anesthesia). The investigators are conducting this study to see whether patients taking pyridostigmine are more or less sensitive to rocuronium (a muscle relaxing medication used during surgery).

Detailed Summary: No subjects enrolled. No data collected.
Sponsor: Shashi Bhatt, MD

Current Primary Outcome: Dose of the muscle relaxant rocuronium that will lead to 50% decrease in the force of the evoked muscle contraction in patients taking pyridostigmine. [ Time Frame: 12 months ]

Rocuronium used to produce muscle weakness or paralysis during surgery. Its potency is measured as ED50, the dose necessary to cause a 50% reduction in the force of evoked muscle contraction. We intend to determine this measure of potency (ED50 for rocuronium) in patients taking pyridostigmine and compare it with control subjects.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Toledo Health Science Campus

Dates:
Date Received: May 21, 2014
Date Started: March 2014
Date Completion:
Last Updated: July 15, 2016
Last Verified: July 2016